8-K: Pulmonx Reports Mixed Q4, Full Year 2025 Results

Pulmonx Corporation announced its fourth quarter and full year 2025 financial results, showing full-year revenue growth and reduced losses despite a Q4 revenue decline.

Summary

• Full year 2025 worldwide revenue reached $90.5 million, an 8% increase over 2024 (7% on a constant currency basis).
• Fourth quarter 2025 worldwide revenue was $22.6 million, a 5% decrease from Q4 2024 (7% decrease on a constant currency basis).
• Full year 2025 net loss was $54.0 million, or $1.33 per share, an improvement from $56.4 million ($1.44 per share) in 2024.
• Fourth quarter 2025 net loss was $10.4 million, or $0.25 per share, an improvement from $13.2 million ($0.33 per share) in Q4 2024.
• Gross margin was 78% in Q4 2025 and 74% for the full year 2025.
• Operating expenses decreased by 11% in Q4 2025 to $27.4 million, but increased 1% for the full year to $120.8 million.
• Refinanced existing debt, securing up to $60 million in committed capital under a new 5-year interest-only credit facility that extends the debt maturity out to 2031.
• Executed a cost restructuring initiative to reduce operating expenses while maintaining key commercial and clinical investments in growth.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting a strategic pivot towards financial discipline and improved profitability metrics, despite a temporary dip in Q4 revenue and flat 2026 revenue guidance.

Positives

• Full year 2025 worldwide revenue increased by 8% to $90.5 million.
• Full year 2025 net loss improved to $54.0 million from $56.4 million in 2024.
• Fourth quarter 2025 net loss improved to $10.4 million from $13.2 million in Q4 2024.
• Fourth quarter 2025 gross margin increased to 78% from 74% in Q4 2024.
• Operating expenses decreased by 11% in Q4 2025.
• Successful refinancing of existing debt, securing up to $60 million in committed capital with extended maturity to 2031.
• Implementation of a cost restructuring initiative to reduce operating expenses.
• International revenue grew 23% for the full year 2025 and 8% in Q4 2025.
• Adjusted EBITDA loss improved in both Q4 2025 ($5.5 million vs $7.5 million) and full year 2025 ($30.6 million vs $31.3 million).
• Expected decrease in cash burn for full year 2026 to approximately $23 million, down from $32 million in 2025.

Negatives

• Fourth quarter 2025 worldwide revenue decreased by 5% to $22.6 million.
• U.S. revenue decreased by 11% in Q4 2025 and only increased 1% for the full year 2025.
• Cash, cash equivalents, and marketable securities decreased by approximately $32 million in 2025 to $69.8 million.
• Full year 2026 revenue guidance of $90 million to $92 million suggests flat to minimal growth compared to $90.5 million in 2025.

Risks

• Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified.
• Factors that could cause actual results to differ materially are found in the Risk Factors section of SEC filings, including the Quarterly Report on Form 10-Q for the period ended September 30, 2025.

Future Outlook

Pulmonx expects full year 2026 revenue to be between $90 million and $92 million, with gross margin approximately 75%. Total operating expenses are projected to be $113 million to $115 million, including $21 million of non-cash stock-based compensation. The company anticipates cash, cash equivalents, and marketable securities to decrease by approximately $23 million for the full year 2026, assuming no additional drawdowns from the credit facility.

Management Comments

• "While our recent performance reflects a period of transition, we see a substantial opportunity to rebuild momentum through a clear operating plan focused on our highest-impact initiatives, including reaccelerating commercial growth and advancing our clinical pipeline." Glen French, President and Chief Executive Officer.
• "We have strengthened our balance sheet and are executing with increased focus and financial discipline to align investments with growth expectations to support a sustainable path to profitability." Glen French, President and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that the medical device sector, particularly for chronic conditions like COPD, often sees companies balancing growth investments with profitability. Pulmonx's focus on cost restructuring and strengthening its balance sheet, alongside continued investment in commercial growth and clinical pipeline, reflects a common strategy in this industry to navigate market dynamics and achieve sustainable long-term value. The flat revenue guidance for 2026, despite full-year 2025 growth, suggests a strategic pivot towards efficiency and profitability over aggressive top-line expansion in the near term.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark Pulmonx's performance against industry standards. Therefore, a direct comparison is not possible based solely on this document.

Stakeholder Impact

• Shareholders: Potential for improved long-term profitability and reduced cash burn, but near-term revenue growth is flat. Debt refinancing provides financial stability.
• Employees: Cost restructuring initiative may imply workforce adjustments, though not explicitly stated.
• Customers: Continued investment in commercial and clinical initiatives suggests ongoing product development and support.
• Creditors: Debt refinancing extends maturity and provides committed capital, improving the company's financial flexibility.

Next Steps

• Reaccelerate commercial growth.
• Advance the clinical pipeline.
• Execute with increased focus and financial discipline to align investments with growth expectations.
• Host a conference call on March 4, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and 2026 guidance.

Key Dates

Recommendation

The company is in a "period of transition" with mixed results, showing full-year revenue growth but a Q4 decline and flat revenue guidance for 2026. While profitability metrics are improving and the balance sheet has been strengthened through debt refinancing and cost restructuring, the lack of significant top-line growth in the near term suggests a "hold" position. Investors should monitor the execution of the operating plan to reaccelerate commercial growth and advance the clinical pipeline for signs of renewed momentum before considering a stronger position.

Keywords

Pulmonx, LUNG, financial results, Q4 2025, full year 2025, 2026 guidance, revenue, net loss, gross margin, operating expenses, debt refinancing, cost restructuring, COPD, Zephyr Valve, medical devices, minimally invasive treatments